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Treatment of advanced cutaneous melanoma remains challenging, and new data on mela-
noma biology are required. The most widely accepted criteria for the prognostic evaluation
of melanoma are histopathological and clinical parameters, and the identification of addi-
tional tumor markers is thus of paramount importance. Matrix-assisted laser desorption/ioni-
zation mass spectrometry imaging (MALDI MSI), an important tool in cancer research, is
useful for unraveling the molecular profile of melanoma.
Methodology/Principal findings
In this report, we used the melanoma-bearing Libechov minipig (MeLiM), a unique animal
model that allows observation of the complete spontaneous regression of invasive cutane-
ous melanoma, to investigate i) the differences between melanoma and healthy skin protein
profiles and ii) the proteins potentially involved in spontaneous regression. The MeLiM tis-
sues were cryosected, histologically characterized, analyzed by MALDI MSI, and immuno-
histologically stained. Multivariate statistical analyses of the MALDI MSI data revealed ten
relevant m/z ions, of which the expression levels varied significantly among the studied
MeLiM tissues. These ion peaks were used to create mass ion images/maps and visualize
the differences between tumor and healthy skin specimens, as well as among histologically
characterized tissue regions.
Conclusions/Significance
Protein profiles comprising ten statistically significant mass ion peaks useful for differentiat-
ing cutaneous melanoma and healthy skin tissues were determined. Peaks at m/z 3044,
6011, 6140 and 10180 were overexpressed in melanoma compared with healthy skin tissue.
More specifically, m/z 6140 was expressed at significantly (p < 0.05) higher levels in nor-
mally growing melanoma regions than in regions with early and late spontaneous regres-
sion. This study demonstrates the clinical utility of MALDI MSI for the analysis of tissue
cryosections at a molecular level.
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Introduction
Melanoma is one of the most aggressive forms of cancer, being responsible for 1.2% of all can-
cer deaths in the European Union. Cancerous growth develops when unrepaired DNA damage
to skin cells (most often caused by ultraviolet radiation from sunlight or tanning beds) triggers
mutations that cause the skin cells to multiply rapidly and form malignant tumors [1]. Cancer
cells and/or the surrounding microenvironment generate proteins and peptides of different
types and in different concentrations than normal cells during cancer development [2]. Pro-
tein changes associated with the transition from melanocyte to atypia or dysplasia and ulti-
mately to melanoma could be used to aid in diagnosis or to screen high-risk patients. Proteins
associated with pathophysiology and malignant properties could be used to further classify
melanoma, stratifying patients by risk of recurrence in order to better select surgical and adju-
vant treatments [3]. Beyond the diagnostic and prognostic value in assessing melanoma pro-
gression, these protein signatures may provide valuable insights into the choice of optimal
treatment strategies for individual patients. The most widely accepted criteria for the prognos-
tic evaluation of melanoma are histopathological and clinical parameters, and the identifica-
tion of additional tumor markers is thus of paramount importance.
Matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI MSI) is a
label-free technique for spatially resolved molecular analysis of tissue sections [4, 5]. MALDI MSI
has a high potential to support histopathological diagnosis [6], and increasing research activity has
been aimed at establishing clinical applications of this technology [7]. Furthermore, it is a valuable
method for the identification of biomarkers and can complement histology, immunohistochemis-
try and molecular pathology in various fields of histopathological diagnostics, especially with
regard to the identification and grading of tumors [8]. Many studies have demonstrated that
MALDI MSI can be used for biomarker discovery [9–11] and, more importantly, for tumor classi-
fication [12, 13] and the determination of the origin of the primary tumor [14].
Spontaneous animal tumors appear to be highly suitable models with which to study human
oncology and cancer therapy [15]. The melanoma-bearing Libechov minipig (MeLiM) strain of
miniature pigs with heritable cutaneous melanoma is an original animal cancer model with his-
topathological, biochemical and molecular biological similarities to human melanoma [16, 17].
The MeLiM strain allows observation of the complete spontaneous regression of invasive cuta-
neous melanoma. Thus, it is an excellent model for discovering biomarkers possibly involved in
this process. A recent study applied laser ablation inductively coupled plasma mass spectrome-
try (LA ICP MS) to spatially map metals in histologically specified regions in MeLiM melanoma
[18]. The levels of Zn and Cu in given regions varied, suggesting a connection with the expres-
sion of metal-binding proteins such as tyrosinase, Tyrp 2/Dct or metallothioneins (MTs) [18].
The abnormal distribution of proteins in tissue can be analyzed by MALDI MSI, and the pat-
terns may help to identify cancer-specific changes (compared with controls) that may prove to
be clinically useful [2].
The goal of the present study was to compare the expression levels of particular proteins/
peptides in very small, histologically uniform and mutually distinct regions of melanoma sam-
ples, providing an efficient method for monitoring changes in protein levels during spontane-
ous regression in the MeLiM model.
Materials and methods
Materials
Sinapinic acid (SA), 2,5-dihydroxybenzoic acid (DHB) and all solvents (HPLC grade) used
were purchased from Sigma-Aldrich (MO, USA), unless otherwise noted. Conductive indium-
MALDI MSI of MeLiM melanoma: Diagnostic markers
PLOS ONE | https://doi.org/10.1371/journal.pone.0189305 December 8, 2017 2 / 15
which is co financed by the South Moravian Region
under grant agreement No. 665860.
Competing interests: The authors have declared
that no competing interests exist.
tin oxide (ITO) one-side coated glass slides and peptide and protein calibration standards
were purchased from Bruker Daltonik GmbH (Germany).
Sample collection
Two MeLiMs (both 10 weeks old) with multiple skin nodular melanomas (20–38 mm in size)
were used in this pilot experiment. One melanoma was excised from each animal under total
anesthesia [premedication with intramuscular (i.m.) administration of 0.5 mg.minipig-1 atro-
pine (Hoechst-Biotika, Slovak Republic), followed by 1 mg.kg-1 of body weight Stresnil (Janssen
Pharmaceutica N.V., Belgium) and Narcotan inhalation (Leciva, Czech Republic)]. The wound
was closed by individual stitches, and Vetalgin (0.5 mg.kg-1 of body weight; Intervet Interna-
tional, Germany) was administered i.m. after the surgery was finished and for two days thereaf-
ter to control pain after tumor excision and wound suturing. The overall health status, food
intake, physical activity and wound healing were monitored in both experimental animals twice
a week for 2 weeks after tumor excision. The wounds were completely healed at that time, so
the stitches were removed. This experimental treatment was performed in accordance with the
rules of the European Convention for the Care and Use of Laboratory Animals and on the basis
of the Project of Experiment that was assessed and recommended by the Expert Committee of
the IAPG AS CR, v.v.i. (Libechov, Czech Republic) for ensuring the welfare of experimental ani-
mals and approved by the Expert Committee of the Academy of Sciences of the Czech Republic.
Sample preparation
Tissue blocks were prepared according to the following protocol, which were suggested by
Anyz et al. [18]. Serial cryosections (8 μm thickness for histology and immunohistochemistry
and 6–10 μm thickness for MALDI MSI optimization) were prepared by a Leica CM 1850-
Cryostat (Leica, Germany). Cryosections for MALDI MSI were mounted onto ITO glass slides
and stored at -80˚C. Prior to analysis, the slides were warmed by hand and desiccated under
vacuum for 15 min. Then, the slides were washed in a Coplin jar with ethanol (twice in 70%
ethanol for 2 min and once in 100% ethanol for 2 min), followed by several washings with cold
ACS-grade water (10 short dips) and subsequent washing with ethanol as indicated. The
matrix application samples were dried under vacuum for 15 min, and the positions of the tis-
sue slices were marked with three guide marks using a white pencil corrector. Afterwards, the
glass slides were scanned by an Epson Perfection V500 Office scanner (Epson Europe B.V.,
Netherlands) at a resolution of 2400 DPI.
Histology
Hematoxylin-eosin staining was applied to observe tissue structure. Cryosections were fixed
with ethanol (20 min), washed with distilled water (three times, 5 min each) and treated with
Weigert’s hematoxylin (20 min) for nuclei staining. Then, the cryosections were washed with
running tap water (20 min), followed by distilled water (three times, 5 min each). The cyto-
plasm was counterstained with 1% eosin alcoholic solution (1 min). After washing with dis-
tilled water (three times, 5 min each), the stained sections were embedded in glycerin jelly.
Whole cryosections were scanned by a VS120 Olympus microscope with OlyVIA software
(Olympus, Japan). In the scanned images, GIMP 2.8 software (http://www.gimp.org/) was
used to identify three histologically different regions of melanoma tissue. Zones of growing
melanoma tissue (GMT) were made up of darkly pigmented intact melanoma cells in close
proximity to one another (Fig 1A). Zones of early spontaneous regression (ESR) showed lym-
phocyte infiltration that resulted in the destruction of some melanoma cells and the formation
of large extracellular spaces. However, most melanoma cells were still well preserved (Fig 1B).
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In regions of late spontaneous regression (LSR), most melanoma cells were already destroyed,
forming extensive cellular debris. Intact melanoma cells were only sparsely dispersed (individ-
ually or in small groups), and initial rebuilding of tumor tissue in the fibrous tissue was locally
observed (Fig 1C). In healthy normal black skin, six standard histological structures were mon-
itored—epidermis, dermis, hair follicles, sweat glands, subcutaneous adipose tissue, and sub-
cutaneous muscle tissue. Three to six rectangular areas of each region per cryosection were
chosen for comparison of the protein maps to detect the local protein contents.
Matrix application
MALDI matrix was sprayed onto ITO glass slides using ImagePrepTM standard programs
(Bruker Daltonik GmbH, Germany). The following MALDI matrices were used: 10 mg.ml-1
SA in acetonitrile/water (60:40, v/v) with 0.2% trifluoroacetic acid (TFA) and 30 mg.ml-1 DHB
in methanol/water (50:50, v/v) with 0.2% TFA. The MALDI matrix mixtures were thoroughly
vortexed and ultrasonicated in a Bandelin 152 Sonorex Digital 10P ultrasonic bath (Bandelin
electronic GmbH, Germany) for 2 min at 50% intensity at room temperature (RT). The slides
were ready for analysis after drying in a vacuum desiccator for 15 min.
MALDI MSI analysis
MSI was performed on a Bruker ultrafleXtreme MALDI tandem time-of-flight (MALDI-TOF/
TOF) mass spectrometer (Bruker Daltonik GmbH, Germany). The total sample set consisted
of 12 ITO glass slides containing 24 tissue sections. The scanned images of tissue slices were
loaded into FlexImaging 3.0 software (Bruker Daltonik GmbH, Germany), and a MALDI
adapter with two ITO glass slides was loaded into the mass spectrometer. The position of the
MALDI adapter was adjusted according to the white guide marks on the ITO glass slides. The
regions of acquisition were highlighted by the mouse pointer in FlexImaging, and 50 μm raster
width was chosen. External calibration was performed using a peptide and protein standard
mixture in an m/z range of 1–20 kDa. The intensity of each scan over the entire acquired mass
range was mapped on the tissue section image to visualize the location of each m/z value de-
tected. These images were generated and visualized using SCiLS Lab 2014b software (SCiLS–
Bruker Daltonik GmbH, Germany). The laser power was set to 85% for the SA matrix and
80% for the DHB matrix. MALDI MSI of proteins was performed in linear positive mode in a
m/z range of 1-20 kDa. A total of 500 spectra were summed for each spot using a random walk
raster pattern, with no evaluation criteria. Prior to this study, the tissue thickness and laser
shots per raster spot were optimized. Sections of various thickness (from 6 to 10 μm), rasters of
Fig 1. Histologically differing regions identified in hematoxylin-eosin-stained skin melanoma of a
10-week-old MeLiM. (A) Growing melanoma tissue (GMT), (B) melanoma tissue with early spontaneous
regression (ESR), and (C) melanoma tissue with late spontaneous regression (LSR) (scale bar = 20 μm).
https://doi.org/10.1371/journal.pone.0189305.g001
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various dimensions (30×30, 50×50, 100×100 and 200×200 μm) and different numbers of laser
shots per raster spot (300, 500, 1000 and 1200 laser shots per raster spot) were tested.
Spectral processing and statistics
The MSI data from FlexImaging were converted and uploaded into the SCiLS Lab software used
for pipeline preprocessing, segmentation and statistical analysis [namely, principal component
analysis (PCA), the Anderson-Darling normality test and the Kruskal-Wallis test]. The preprocess-
ing pipeline applied baseline removal using the iterative convolution algorithm with sigma = 20
and iterations = 20. Subsequently, the total ion current (TIC) of every spectrum was normalized to
one. At the same time, the mean spectrum was calculated. The segmentation pipeline applied the
spectral group resulting from the preprocessing pipeline to find peaks using orthogonal matching
with sigma estimated from the mean spectrum. This process found a maximum of 50 peaks per
spectrum and was applied to every 15th spectrum. The consensus threshold was 1%. Then, a peak
alignment was applied to the resulting histogram peak list together with the mean spectrum.
Finally, the denoising and segmentation pipeline was applied to the spectral group produced by
the preprocessing pipeline, and the peak list was produced by the peak alignment. The denoising
level was the same as that selected in the settings of the segmentation pipeline.
The Anderson-Darling normality test revealed that the distribution of MSI data was not
normal (p< 0.001). Therefore, the Kruskal-Wallis test was used for all hypothesis tests. The
significance of differences in the peak intensities of selected masses between healthy skin and
melanoma, between each region of interest (ROI) on healthy skin and between each ROI of
melanoma was tested.
PCA of the MSI data of peaks selected in the segmentation pipeline was performed after the
data were normalized using the preprocessing pipeline. Unit variance scaling was used.
An intensity box plot chart conveniently depicts the intensities of a given m/z range in the
spots of a given region through their quartiles. Every box describes a single m/z range and a
single region. Every plot consists of two parts: a box and a cloud. The box contains a rectangle
divided by a horizontal line, which represents the median intensity. The median intensity is
defined such that the number of spots with lower values than the median intensity is equal to
the number of spots with higher intensity. The lower and upper bounds of the box represent
the second and third quartile, respectively, which means that the total number of spots with
intensities below these lines are one-quarter and three-quarters, respectively. The lines extend-
ing vertically from the boxes (whiskers) represent the lower and upper quantiles, respectively,
which are 0.0% and 99.0%, respectively, by default. The cloud part of the plot shows how spots
in a given region are spread by the intensity of a given m/z range. Blue dots represent the spots
in which the intensities of a given m/z range are between the lower and upper quantiles. Red
dots represent the spots with intensities outside of these intensity intervals, so-called “outliers”.
MSI image preparation
Final preparation of the MSI images was carried out in SCiLS Lab software. According to PCA
and the Kruskal-Wallis test, ion peaks with significant variability between melanoma and
healthy skin tissues were used to create the MSI images. Each m/z value was displayed as “m/z
± 1.5 Da”. Final corrections and preparations of the MALDI MSI images were carried out in
GIMP 2.8 software.
Immunohistochemistry
The cryosections were incubated for 10 min at RT with phosphate-buffered saline (PBS).
Endogenous peroxidase activity was blocked with 3% H2O2 in PBS for 15 min. After washing
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with dH2O, heat-induced epitope retrieval was performed using citrate buffer (10 mM, pH
6.0). After washing in PBS, the sections were incubated first with anti-MT-1 and MT-2 anti-
body (Dako, M0639, 1:50) for 1 hr at RT, followed by incubation with horseradish peroxidase
(HRP)-conjugated rabbit anti-mouse antibody (Dako, P0260, 1:100) for 15 min at RT. The sec-
tions were developed with the 3-amino-9-ethylcarbazole (AEC) Substrate Kit, counterstained
with hematoxylin and, after drying, mounted with aqueous mount.
Results
MALDI MSI analysis
Fresh frozen melanoma tissues from two MeLiMs were analyzed using MALDI MSI, and the
resulting data were compared with data from matching healthy skin tissues stored under the
same conditions. The samples were processed using a solvent washing step prior to peptide/
protein MSI analysis. The MSI data were then imported into SCiLS Lab software for post-pro-
cessing and generation of protein profiles and specific ion maps. The MSI data obtained after
the application of an SA matrix and/or a DHB matrix was not significantly different
(p< 0.05). Utilization of tissues with thicknesses of 8 and 10 μm resulted in satisfactory sensi-
tivity and did not influence the variability of the spatial distribution within a tumor. The opti-
mal number of laser shots per raster spots was found to be at least 500, and the optimal raster
spot dimension was 50×50 μm. A schematic experimental workflow of the MALDI MSI exper-
iment is provided in Fig 2.
Statistical analysis of MALDI MSI spectra
The MALDI MSI spectra obtained from tissue cryosections were submitted to SCiLS Lab soft-
ware to compare the average mass spectra from both tissues (Fig 3A). PCA visualized the vari-
ances between melanoma and healthy skin tissue sections, and the Kruskal-Wallis test revealed
a series of significant (p< 0.001) ion peaks that accounted for the variation (Fig 3B, Table 1).
Fig 2. Schematic of MALDI MSI of MeLiM healthy skin/melanoma tissue.
https://doi.org/10.1371/journal.pone.0189305.g002
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The mass ion peaks at m/z 3044, 3458, 4737, 4967, 6011, 6140, 6654, 6985, 9258 and 10180
appeared in both types of MeLiM tissues. These ion peaks were used to generate MSI images
and intensity box plots to visualize the differences between the melanoma and healthy skin tis-
sue sections (Fig 4, S1 and S2 Figs). The intensities of several mass ion peaks differed between
the two tissue types and revealed the heterogeneity of melanoma tissue. In particular, the peaks
at m/z 3044, 6011, 6140 and 10180 were overexpressed in melanoma (S1 Fig, Table 1), and
those at m/z 3458, 4737, 4967, 6654, 6985 and 9253 were pronounced in healthy skin tissue (S2
Fig, Table 1).
Each melanoma tissue section was split into different ROIs according to the histologically
uniform and mutually distinct regions of normally GMT, ESR and LSR (Fig 5A). The following
ROIs were assigned in the normal skin tissue section: epidermis, dermis, hair follicle, sweat
gland, subcutaneous adipose tissue and subcutaneous muscle (Fig 5B). The total spectra of
these ROIs were analyzed via PCA and the Kruskal-Wallis test in SCiLS Lab software. Ion
Fig 3. A) Average mass spectra and B) PCA scores plot of MeLiM melanoma (blue) and healthy skin (red)
tissue cryosections.
https://doi.org/10.1371/journal.pone.0189305.g003
Table 1. Tentative identification of proteins with significant variation between MeLiM melanoma and healthy skin tissue.
m/z Tentative identification Rating–Kruskal-Wallis Melanoma Healthy skin Reference
3044 <0.001 * -
3458 <0.001 - *
4737 Thymosin β-10 <0.001 - * [19]
4967 <0.001 - *
6011 Metallothionein <0.001 * -
6140 Metallothionein <0.001 * -
6654 <0.001 - *
6985 <0.001 - *
9258 <0.001 - *
10180 S100-A6 <0.001 * - UniProtKB–P06703
(*) Higher expression.
https://doi.org/10.1371/journal.pone.0189305.t001
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peaks with high variability were then used to create the ion images and intensity box plots (S1
and S2 Figs).
The PCA scores and loadings plots of the tumor and healthy skin ROIs are presented in Fig
6. The first two axes represented 99.51% of the total data variance. To further investigate the
Fig 4. MALDI ion images of healthy skin (A) and melanoma (B) tissue from MeLiM cryosections and
intensity box plots (C) of selected m/z values. The peaks at m/z 3044, 6011 and 6140 were overexpressed
in melanoma, and those at m/z 3458, 4737 and 6654 were pronounced in healthy skin tissue. (***) p < 0.001.
https://doi.org/10.1371/journal.pone.0189305.g004
Fig 5. Histology, scan and MSI image of the mass ion peak at m/z 6011 with specified regions of
differentiated tissue sections (differences between MeLiM melanoma and healthy tissue). A) Three
histologically differing regions identified in hematoxylin-eosin-stained skin from porcine melanoma: red–
normally growing melanoma tissue (GMT), violet–early spontaneous regression (ESR), and orange–late
spontaneous regression (LSR). B) Six ROIs determined in healthy skin tissue: red–epidermis, light blue–
dermis, violet–hair follicle, dark blue–sweat gland, orange–subcutaneous adipose tissue, and green–
subcutaneous muscle.
https://doi.org/10.1371/journal.pone.0189305.g005
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differences between the three histologically specified regions within the melanoma tissue, the
Kruskal-Wallis test was applied (S1 Table). Ion peaks at m/z 3044, 3458, 4967 and 10180 varied
significantly (p< 0.05) between the ESR and LSR regions. Comparing the GMT and ESR
regions, the most variable ion peaks were located at m/z 3458 and 6140, while the GMT and
LSR regions differed significantly (p< 0.01) in the expression of ion peaks at m/z 3044, 3458,
4737, 4967, 6140 and 10180 (Fig 6A and S1 Fig). Significant correlations were found between
the ion peaks at m/z 6011 and 6140 (p< 0.05, r = 0.79) and m/z 6984 and 6653 (p< 0.05,
r = 0.72) (S3 Fig). It is probable that the peaks at m/z 6011 and 6140 belong to same molecule;
the m/z difference of 129 could correspond to one glutamic acid molecule. In the healthy skin
tissue, PCA revealed a separation of the subcutaneous muscle region from the regions of hair
follicle, subcutaneous adipose tissue and dermis (Fig 6B). The first two PC axes together ac-
counted for 91.94% of the variance. The ion peaks at m/z 3458, 4737, 4967, 6140, 6654, 6985,
9258 and 10180 varied significantly (p< 0.001) among the six histologically specified regions
within the healthy skin tissue. Notably, m/z 6011 did not vary significantly (p 0.05) in the
healthy skin tissue (S2 and S3 Tables). The ion peaks at m/z 6011 and 6140 were tentatively
identified as MTs. To verify this finding, immunohistochemical detection of MT-1 and MT-2
was performed (S4 Fig). In healthy skin, MT positivity was detected in the dermis and epider-
mis, which is consistent with the MSI results. However, due to strong pigmentation, no posi-
tivity or negativity for MT could be detected in the melanoma tissue.
Discussion
The protein signatures of melanoma and healthy skin exhibited different characteristics, which
is in accordance with the previously published studies. More differentially expressed proteins
were observed at higher intensity in the healthy skin tissues, whereas fewer proteins with
Fig 6. A) PCA scores and loadings plots of three histologically differentiated regions of MeLiM melanoma
(inset). Red–normally growing melanoma tissue (GMT), violet–early spontaneous regression (ESR), and
orange–late spontaneous regression (LSR). B) PCA scores and loadings plots of six ROIs in healthy skin
tissue (inset). Red–epidermis, light blue–dermis, violet—hair follicle, dark blue–sweat gland, orange–
subcutaneous adipose tissue, and green–subcutaneous muscle.
https://doi.org/10.1371/journal.pone.0189305.g006
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higher intensities were expressed in MeLiM melanoma specimens. In total, the intensities of
ten ion peaks, m/z 3044, 3458, 4737, 4967, 6011, 6140, 6654, 6985, 9258 and 10180, signifi-
cantly differed between melanoma and healthy skin tissue. Four ion peaks, m/z 3044, 6011,
6140 and 10180, were more highly expressed in melanoma tissue. The molecular weight of cys-
teine-rich metal-binding proteins, MTs, is approximately 6–7 kDa, which correlates with the
characteristic mass peaks at m/z 6011 and 6140 observed here in MeLiM melanoma tissues.
The calculated masses of porcine MTs according to the UniProtKB database are 5969 Da for
MT-1A, 5970Da for MT-2A, 5998 Da for MT-2B, 5969 Da for MT-1E, 5955 Da for MT-1F,
5959 Da for MT-1C, 5975 Da for MT-1D and 6927 Da for MT-3 (UniProt entries P49068,
P79379, P79380, P79431, P79378, P79376, P79377, and P55944, respectively). Based on a com-
parison of the obtained results, m/z 6011 and 6140 may be partially metalated MT-1 or MT-2,
as metals might be partly removed from the MT molecule after interaction with the matrix
solution due to the low pH [20]. Furthermore, the intensity of m/z 6140 varied significantly
between the ESR and LSR regions and the GMT region. This peak, together with m/z 6011 and
3044, was overexpressed in the GMT region. Moreover, the overexpression of m/z 6011 and
6140 in the GMT region agrees with the higher content of zinc ions detected in the same
region in our previous study [18]. These findings are in accordance with our assumption that
the peaks at m/z 6011 and 6140 correspond to MT. MT expression by tumor cells may increase
the development of melanoma, resulting in increased tumor survival and thus increased carci-
nogenesis. MT can reduce tyrosinase activity and melanogenesis in melanocytes, suggesting
that the presence of MT prior to tumor initiation may be protective against tumor develop-
ment [21]. MT overexpression has been shown to be more significantly associated with tumor
progression than the established surgical prognostic test based on a sentinel lymph node
biopsy [22]. A positive correlation between MT expression and tumor thickness, invasive
capacity, and a higher risk of progression was previously reported [22–24]. Specifically, overex-
pression of MT has been found in human cutaneous malignant melanomas associated with a
poor prognosis [24–26]. Moreover, overexpression of a positive MT regulator (cancer-testis
antigen 16) has been shown in melanoma metastasis [27]. In the MeLiM tumor tissue, an ele-
vated total MT content (500 μg of MTs per gram of tissue) was previously identified by an
adsorptive transfer stripping technique, the Brdicka reaction [28].
In this work, MT-1 and MT-2 expression in healthy skin correlated with the localization of
mass peaks m/z 6011 and 6140. However, in melanoma tissue, immunohistochemical detec-
tion was not possible due to the high melanin content, which interferes with staining. Several
procedures for melanin bleaching of tissue sections have been published but with compro-
mised results. Demelanization of extremely pigmented samples often leads to destruction of
the tissue antigen and architecture and even to degradation of the chromogen precipitate [29].
As natural pigmentation is a frequent problem in immunohistochemistry, new non-optical
detection methods are desired. Mass-spectrometry methods, either label-free methods such as
MALDI MSI or employing metal labels such as laser-induced breakdown spectroscopy (LIBS)
or ICP-MS, have the potential to overcome this difficulty [30–32]. Several tissue markers,
including S100, MART-1, gp100/HMB45 and/or MT, are used to help distinguish melanoma
from other types of cancer [26]. To date, however, there are no tissue-based biomarkers that
are utilized clinically for prognostic classification [3]. In the GMT regions of the MeLiM tis-
sues, we observed higher expression of m/z 6011 and 6140, which were positively correlated
with each other and were assigned to MTs. Modified MT expression was previously deter-
mined in human tumors and was correlated with tumor invasiveness and a poorer prognosis,
as mentioned above.
In histology-directed MALDI MSI profiling of human melanoma lymph node tissue, Hard-
esty and coworkers identified overexpression of several ion peaks, e.g., at m/z 3744, 4737, 8963
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and 10625, compared with cancer-free lymph nodes [19]. These authors used a top-down
approach to identify specific proteins that could be used to determine the disease stage and the
inclusion of patients into either a poor or favorable group for recurrence and survival. The
proteins identified in the signatures were cytochrome c, S100-A6, histone H4 and cleaved
forms of thymosin β-4 and thymosin β-10 (TYB-10-2AA). In the present study, m/z 4737,
which probably corresponds to TYB-10-2AA, was overexpressed in healthy skin tissue. Thy-
mosin β proteins sequester actin monomers within the cell, inactivating polymerization until
needed.
The S100 protein family, which is involved in Ca2+ homeostasis, the regulation of protein
phosphorylation and cell growth and proliferation, was previously found to be expressed in
early melanoma stages [33, 34]. The molecular weight of S100 proteins is approximately 10
kDa, which corresponds to the ion peak at m/z 10180 that was expressed in the ESR and GMT
regions than in the LSR regions of the MeLiM melanoma tissue. The peak at m/z 10180 is
probably S100-A6 protein (calcyclin), according to the UniProt database (UniProtKB—
P06703). Calcyclin expression was observed in diverse cancers and was previously identified
by mRNA analysis as a potential marker for aggressive melanoma [35, 36]. Moreover, calcyclin
expression was higher in cells showing stronger higher Clark levels (> II), which corresponds
to the vertical growth of primary melanoma cells. The overexpression of S100-A6 in the of
GMT and ESR regions in MeLiM tissue confirms the findings of the abovementioned studies
suggesting the use of calcyclin overexpression as an indicator of melanoma growth.
Conclusion
This pilot study demonstrates that MALDI MSI can successfully visualize the spatial distribu-
tion of various proteins in melanoma and healthy skin tissue from MeLiM. Using suitable MSI
statistical software, in our case SCiLS Lab, the significant mass peaks were detected, and the
differences between melanoma and healthy skin were visualized.
In MeLiM melanoma, the mass peaks at m/z 3044, 6011, 6140 and 10180 were significantly
(p< 0.001) overexpressed, whereas in MeLiM healthy skin, the mass peaks at m/z 3458, 4737,
4967, 6654, 6985 and 9258 were significantly (p< 0.001) overexpressed. The occurrence of the
peaks at m/z 6011 and 6140 in the GMT regions was significantly (p< 0.05, r = 0.79) corre-
lated; these peaks were tentatively identified as the metal-binding protein MT. The overexpres-
sion of m/z 6011 and 6140 was observed in the normally GMT region and correlates with the
higher content of zinc ions found in the identical MeLiM tissue region [18, 28]. Moreover, the
significantly (p< 0.05) higher expression of the peak at m/z 6140 in the GMT region than in
the ESR and LSR regions suggests that this protein is associated with melanoma growth. The
peak at m/z 10180 was tentatively identified as the protein S100-A6 according to the Uni-
ProtKB (P06703) database. The peak at m/z 4737 was tentatively identified as thymosin β-10
lacking two amino acids according to the study of Hardesty and coworkers [19]. In analyzing
the MeLiM tissue by MALDI MSI, each of the tentatively identified proteins (specifically, MT,
S100-A6 and thymosin β-10) could be monitored individually within a single experiment,
enabling multiplex signature generation for the improvement of melanoma diagnostics.
The exact identification of the detected peaks by on-tissue trypsinization followed by MAL-
DI-TOF/TOF analysis was not feasible in the present study because of the limited amount of
the tissue samples. In the near future, we will focus on the exact identification of detected
peaks either by MALDI-TOF/TOF or by the extraction of proteins from homogenized mela-
noma samples and their separation by 2D PAGE and in-gel trypsinization followed by MAL-
DI-TOF/TOF or high-performance liquid chromatography coupled to electrospray ionization
and quadrupole time-of-flight mass spectrometry (HPLC-ESI-qTOF MS) analysis.
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In conclusion, our results contribute to the basic knowledge of the protein distribution in
histologically specified regions in MeLiM tissues and will be used in further experiments
aimed at elucidating the processes involved in spontaneous melanoma regression.
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